

Table S1. Further characteristics.

Characteristic	Frequency (in %)
Number of medication	No medication
	13.2%
	1 to 4
Medication Groups	44.7%
	≥5
	42.1%
Medication Groups	Analgetic
	7.9%
	Antihypertensive
	55.3%
	Antiplatelets/Anticoagualtes
	71.1%
	Statins
	42.1%
	Anti-diabetic
	7.9%
	Anti-depressants
	26.3%
	Anti-inflammatory
	7.9%
	Cholesterol-lowering medication
	2.6%
	Thyroid medication
	5.3%
	Proton pump inhibitors
	21.1%
Comorbidities	Anti-rheumatic
	2.6%
	Anti-epileptic
	5.3%
	Muscle relaxant
	15.8%
	Immunosuppressiva
	2.6%
	Other
	26.3%
	No comorbidities
	14.8 %
	Diabetes
	18.5 %
	Peripheral vascular
	14.8 %
	Cerebrovascular disease
	18.5 %
	Congestive heart failure
	11.1 %
	Respiratory disease
	7.4 %
	Tumor
	11.1 %
	Rheumatologic disease
	18.5 %
	Musculoskeletal problems
	18.5 %
	Renal disease
	7.4 %
	Psychiatric problems
	11.1 %
	Other
	18.5 %
	missing <i>n</i> = 11
Affected areas	Gait
	78.9%
	Hand and arm function
	71.1%
	Concentration and/or memory
	57.9%
	Pain
	36.8%
Affected areas	Mood
	39.5%
	Speaking
	34.2%
	Vision
	31.6%
	Other
	15.8%

Legend: Self-reported information. Multiple responses were possible.

Table S2. Analysis of SF-36 pre- and post-intervention results ($n = 38$).

	pre	post	Statistics			
	M \pm SD	M \pm SD	df	t-Test	Wilcoxon signed-rank	p-value
Bodily Pain	61.8 \pm 26.6	68.0 \pm 23.2	37	NA	W = 83.5, z = -1.900	0.059
Physical Functioning	51.7 \pm 25.9	60.8 \pm 26.6	35	NA	W = 91.5, z = -2.725	0.006
Mental Health	59.9 \pm 23.6	71.9 \pm 18.6	36	t = -4.249	NA	<0.001
Role limitations due to emotional health	57.9 \pm 45.0	63.6 \pm 46.2	37	NA	W = 91.0, z = -0.523	0.607
Vitality	44.4 \pm 21.9	57.0 \pm 20.5	37	t = -5.572	NA	<0.001
Social functioning	66.7 \pm 31.1	73.6 \pm 26.7	35	NA	W = 93.0, z = -1.088	0.265
General health	52.8 \pm 15.4	53.1 \pm 18.4	37	NA	W = 270.5, z = -0.729	0.468
Role limitations due to physical health	37.5 \pm 35.7	45.6 \pm 42.6	37	-1.107	NA	0.275

Legend: Bold are statistically significant results; df = degrees of freedom, t-test or Wilcoxon signed-rank test.

Table S3. General health questions results pre- and post-intervention ($n = 38$).

	Pre	post	Statistics (Wilcoxon Signed Rank-Test)			
[0–10]	Md [IQR]	Md [IQR]	df	W	z	p
Walking	6 [3]	7 [4]	36	89.0	-2.197	0.027
Speaking	9 [1]	9 [3]	36	107.0	-0.295	0.769
Mood	8 [4]	8 [3]	36	104.5	-1.803	0.066
Vision	8 [3]	8 [3]	36	151.0	-0.913	0.358
concentration	7 [4.25]	8 [3]	35	90.5	-1.937	0.048
Sleep	8 [4]	8 [2]	36	193.0	-1.078	0.267

Current health	6 [3[7 [2]	36	141.0	-1.882	0.052
memory	7 [4]	8 [4]	35	142.0	-0.851	0.394

Legend: df = degrees of freedom; Md = Median; IQR = interquartile range.

Table 4. Pre- and post-intervention results of the Timed Up and Go test and walking speed.

		Total (<i>n</i> = 38)	MRS 1 (<i>n</i> = 11)	MRS 2 (<i>n</i> = 23)	MRS 3, 4 (<i>n</i> = 4)
		M ± SD	M ± SD	M ± SD	M ± SD
Timed Up and Go (in s)	pre	13.3 ± 4.9	11.4 ± 4.9	13.0 ± 3.8	20.1 ± 5.7
	post	14.2 ± 9.9	9.4 ± 2.3	13.6 ± 5.5	30.8 ± 22.5
	Statistics (Wilcoxon signed-rank test)	W = 303.5, p = 0.857	W = 35, p = 0.476	W = 107, p = 0.781	NA
Gait speed (in m/s)	pre	0.67 ± 0.27	0.86 ± 0.32	0.65 ± 0.19	0.36 ± 0.11
	post	0.69 ± 0.40	0.94 ± 0.60	0.60 ± 0.24	0.49 ± 0.30
	Statistics (t-test)	t = -0.310, df = 31, p = 0.759	T = -0.63, df = 8, p = 0.546	t = 1.060, df = 18, p = 0.303	t = -1.326, df = 3, p = 0.277

Legend: Gait speed was measured with the 4m gait test. M = mean, SD = standard deviation, df = degrees of freedom.